Brief: Biomx Announces Completion Of Patient Dosing In Part 2 Of The Phase 1B/2A Study Evaluating Bx004 For Treatment Of Chronic Pulmonary Infections In Patients With Cystic Fibrosis
Oct 4 (Reuters) - Biomx Inc PHGE.A :
* BIOMX ANNOUNCES COMPLETION OF PATIENT DOSING IN PART 2 OF
THE
PHASE 1B/2A STUDY EVALUATING BX004 FOR TREATMENT OF CHRONIC
PULMONARY INFECTIONS IN PATIENTS WITH CYSTIC FIBROSIS
* BIOMX INC - COMPANY REMAINS ON TRACK TO REPORT PART 2
RESULTS
FROM STUDY IN NOVEMBER 2023
Source text for Eikon: ID:nGNX7Z3C6z
Further company coverage: PHGE.A
((Reuters.Briefs@thomsonreuters.com))
Recent news on Biomx
See all newsBrief: Biomx Inc - Buys 100% Of Zorronet From Water Io - SEC Filing
Brief: BiomX Obtains Option To Acquire Control Of Israeli Laser-Radar Counter-Drone System
Brief: Biomx Adds Former Mossad Deputy To Advisory Board
Brief: Biomx Inc - Jonathan Solomon Resigns As CEO And Board Member Effective March 4, 2026 - SEC Filing
Brief: BiomX Says Unaware of Any Undisclosed Developments Amid Unusual Stock Trading